Drugs that contain Halobetasol Propionate; Tazarotene
1. List of Duobrii drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10478502 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(8 years from now) | |
| US8809307 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(8 years from now) | |
| US10426787 | BAUSCH | Topical compositions and methods for treating psoriasis |
Jun, 2036
(13 years from now) | |
| US10251895 | BAUSCH | Topical compositions and methods for treating psoriasis |
Jun, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Apr 25, 2022 |
Market Authorisation Date: 25 April, 2019
Treatment: Topical treatment of plaque psoriasis in adults
Dosage: LOTION;TOPICAL
How can I launch a generic of DUOBRII before it's patent expiration?
More Information on Dosage
DUOBRII family patents
20
United States
4
Canada
3
Korea, Republic of
3
Brazil
3
Japan
3
European Union
2
Australia
2
Mexico
2
China
1
RS
1
Poland
1
Lithuania
1
Spain
1
Israel
1
Slovenia
1
Hungary
1
Portugal
1
Russia
1
Croatia
1
New Zealand
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic